Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07225036 · ClinicalTrials.gov registry record · NA
Promoting Immunotherapy Efficacy With Low-Dose Liver RT
A NA study of Non-Small Cell Lung Cancer and Melanoma, sponsored by Jordan Kharofa.
- Recruiting
- Registry status
- NA
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT07225036: Recruiting NA study of Non-Small Cell Lung Cancer and Melanoma, sponsored by Jordan Kharofa.
NCT07225036 is a NA study of Non-Small Cell Lung Cancer and Melanoma that is actively recruiting participants, run by Jordan Kharofa. The registered enrollment target is 21 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07225036, a NA study of Non-Small Cell Lung Cancer and Melanoma, is actively recruiting participants, sponsored by Jordan Kharofa.
- RECRUITING
- Registry status
- NA
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to see if adding Low-Dose Liver Radiation (LD-LRT) improves progression free survival (PFS). This study is for patients with either melanoma or non-small cell lung cancer (NSCLC), with liver metastases, and receiving immunotherapy.
Primary Outcome
The primary objective is to evaluate whether the addition of Low-Dose Liver Radiation (LD-LRT) improves progression free survival (PFS) in patients with melanoma and non-small cell lung cancer (NSCLC) with liver metastases receiving immunotherapy. The primary endpoint is 6-month PFS for each cohort compared separately to historical trials with an effect size goal of 25% improvement in 6-month PFS.
Conditions Studied
Interventions
- RADIATION LD-LRT
Study Locations (1)
Ohio
- University of Cincinnati Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2025-12-15 |
| Est. Completion | 2029-12-15 |
| Phase | NA |
What NCT07225036 shows while recruiting
NCT07225036 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (97% lower).
The record links to 4 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which LD-LRT is the first listed.
NCT07225036 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT07225036 about?
NCT07225036 is a clinical study titled "Promoting Immunotherapy Efficacy With Low-Dose Liver RT". The purpose of this study is to see if adding Low-Dose Liver Radiation (LD-LRT) improves progression free survival (PFS). This study is for patients with either melanoma or non-small cell lung cancer (NSCLC), with liver metastases, and receiving immunotherapy.
What is the current status of trial NCT07225036?
This trial is currently recruiting. It is a NA study. The enrollment target is 21 participants. The study started on 2025-12-15. Estimated completion is 2029-12-15.
What conditions does trial NCT07225036 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Melanoma, Liver Metastases, Low-Dose Liver Radiation (LD-LRT).
What interventions are being tested in trial NCT07225036?
The interventions under investigation include: LD-LRT (RADIATION).
Who is sponsoring clinical trial NCT07225036?
This trial is sponsored by Jordan Kharofa, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07225036 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07225036's enrollment target sits among peer trials
21 416th of 454 higher than 36 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dyadic Yoga Program for Patients Undergoing Thoracic Radiotherapy and Their Family Caregivers: The Testing of a Mobile Application Delivery
RECRUITING · NA
-
High-Fermented Food Intervention Among Locally Advanced Rectal Cancer Patients (The FEED Trial)
RECRUITING · NA
-
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
RECRUITING · NA
-
Exercise as Maintenance Therapy in Advanced Lung Cancer
RECRUITING · NA
-
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
RECRUITING · NA
-
Feasibility Testing of a Dyadic Exercise Program for Patients Undergoing Thoracic Radiotherapy and Their Family Caregivers
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI